These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17685741)

  • 21. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder.
    Mohd Ahmed H; Abdel Aziz K; Al Ammari A; Galadari M; Alsaadi A; Alhassani A; Al Marzooqi F; AlAhbabi M; Alsheryani H; Bahayan M; Ahmed R; Alameri S; Stip E; Aly El-Gabry D
    Int J Psychiatry Clin Pract; 2024 Mar; 28(1):35-44. PubMed ID: 38329470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey.
    Nuevo R; Chatterji S; Fraguas D; Verdes E; Naidoo N; Arango C; Ayuso-Mateos JL
    J Clin Psychiatry; 2011 Dec; 72(12):1592-9. PubMed ID: 22244021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation in psychotic disorders: a population-based study.
    Suvisaari J; Loo BM; Saarni SE; Haukka J; Perälä J; Saarni SI; Viertiö S; Partti K; Lönnqvist J; Jula A
    Psychiatry Res; 2011 Sep; 189(2):305-11. PubMed ID: 21798602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and correlates of metabolic syndrome and its components in adults with psychotic disorders in Eldoret, Kenya.
    Kwobah E; Koen N; Mwangi A; Atwoli L; Stein DJ
    PLoS One; 2021; 16(1):e0245086. PubMed ID: 33428652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common familial risk factors for schizophrenia and diabetes mellitus.
    Foley DL; Mackinnon A; Morgan VA; Watts GF; Castle DJ; Waterreus A; Galletly CA
    Aust N Z J Psychiatry; 2016 May; 50(5):488-94. PubMed ID: 26209325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and determinants of metabolic syndrome in Qatar: results from a National Health Survey.
    Al-Thani MH; Al-Thani AA; Cheema S; Sheikh J; Mamtani R; Lowenfels AB; Al-Chetachi WF; Almalki BA; Hassan Khalifa SA; Haj Bakri AO; Maisonneuve P
    BMJ Open; 2016 Sep; 6(9):e009514. PubMed ID: 27601485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis.
    Galletly CA; Foley DL; Waterreus A; Watts GF; Castle DJ; McGrath JJ; Mackinnon A; Morgan VA
    Aust N Z J Psychiatry; 2012 Aug; 46(8):753-61. PubMed ID: 22761397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.
    Basu R; Brar JS; Chengappa KN; John V; Parepally H; Gershon S; Schlicht P; Kupfer DJ
    Bipolar Disord; 2004 Aug; 6(4):314-8. PubMed ID: 15225149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome in people with a psychotic illness: is cannabis protective?
    Waterreus A; Di Prinzio P; Watts GF; Castle D; Galletly C; Morgan VA
    Psychol Med; 2016 Jun; 46(8):1651-62. PubMed ID: 26965714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France.
    Arbus C; Clement JP; Bougerol T; Fremont P; Lancrenon S; Camus V
    Int Psychogeriatr; 2012 Mar; 24(3):496-502. PubMed ID: 21835072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
    Chue P; Mandel FS; Therrien F
    Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
    Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
    Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loneliness in psychotic illness and its association with cardiometabolic disorders.
    Badcock JC; Mackinnon A; Waterreus A; Watts GF; Castle D; McGrath JJ; Morgan VA
    Schizophr Res; 2019 Feb; 204():90-95. PubMed ID: 30243852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan.
    Huang MC; Lu ML; Tsai CJ; Chen PY; Chiu CC; Jian DL; Lin KM; Chen CH
    Acta Psychiatr Scand; 2009 Oct; 120(4):274-80. PubMed ID: 19426161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.